Cargando…
Extended-schedule dose-dense temozolomide in refractory gliomas
This multicenter phase II study conducted by the Spanish Neuro-Oncology Group evaluated the activity of an extended, dose-dense temozolomide regimen in patients with temozolomide-refractory malignant glioma. Adult patients (at least 18 years of age) with WHO grade III or IV glioma and a Karnofsky Pe...
Autores principales: | Berrocal, A., Perez Segura, P., Gil, M., Balaña, C., Garcia Lopez, J., Yaya, R., Rodríguez, J., Reynes, G., Gallego, O., Iglesias, L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808507/ https://www.ncbi.nlm.nih.gov/pubmed/19669096 http://dx.doi.org/10.1007/s11060-009-9980-7 |
Ejemplares similares
-
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010) -
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
por: Taal, Walter, et al.
Publicado: (2012) -
Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era
por: Paravati, Anthony J., et al.
Publicado: (2010) -
Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice
por: van Genugten, J. A. B., et al.
Publicado: (2009) -
Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings
por: Hilverda, Karen, et al.
Publicado: (2009)